HD-OPM Archive
Topics › Blood vessels, circulation & endothelium

Atherosclerotic plaques contain large clonal, mutated cell populations, like tumors

Gokhan Can · Jun 18, 2025 · ♥ 12 reactions · 14 comments · original Facebook post
Blood vessels, circulation & endotheliumPlaque, CAC & CT angiographyInflammation & CRP
AI summary & key facts

A JCI Insight study used deep whole-exome sequencing of carotid plaques and non-atherosclerotic arteries and found somatic mutations in plaques but not in healthy arterial tissue. This suggests plaques grow by clonal expansion, paralleling clonal hematopoiesis (CHIP), which is causally linked to cardiovascular disease.

It is well-established that somatic mutations in blood stem cells, known as clonal hematopoiesis (CHIP), are causally linked to cardiovascular disease and thrombosis.

A parallel paradigm is now emerging in atherosclerosis, where fresh evidence indicates that plaques harbor their own distinct genetic mutations not found in healthy tissue, suggesting they may grow through a process of abnormal clonal expansion.

Article:

medicalxpress.comAtherosclerotic blood vessel cells similarmedicalxpress.com

Paper:

Paper · JCI Insight · 2025Mutational landscape of atherosclerotic plaques reveals large clonal cell populationsThe notion of clonal cell populations in human atherosclerosis has been suggested but not demonstrated. Somatic mutations are used to define cellular clones in tumors. Here, we characterized the mutational landscape of human carotid plaques through whole-exome sequencing to explore the presence of clonal cell populations. Somatic mutations were identified in 12 of 13 investigated plaques, while no mutations were…insight.jci.org

A comprehensive study titled "Mutational landscape of atherosclerotic plaques reveals large clonal cell populations" has provided compelling evidence that human atherosclerotic plaques are characterized by the presence of large, locally expanded populations of cells carrying somatic mutations. The research, led by Lasse Bach Steffensen and Lars Melholt Rasmussen, utilized deep whole-exome sequencing to analyze carotid plaques and non-atherosclerotic arteries, revealing that somatic mutations are a common feature of atherosclerosis but absent in healthy arterial tissue. These findings challenge and refine the long-standing hypothesis of plaque monoclonality and introduce somatic mutations as a powerful new tool for studying the cellular dynamics of this leading cause of cardiovascular disease.

Background and Hypothesis

Atherosclerosis involves the accumulation of lipids, cells, and fibrous elements within the artery wall. The cellular landscape of plaques is complex, originating from both circulating immune cells and local vascular cells, primarily smooth muscle cells (SMCs). For fifty years, since the work of Benditt and Benditt, the idea that plaques might arise from a single ancestral cell (monoclonality) has been debated. Concurrently, recent research has highlighted the role of Clonal Hematopoiesis of Indeterminate Potential (CHIP)—the expansion of hematopoietic stem cells with specific somatic mutations—as a significant risk factor for cardiovascular disease.

Building on this, the researchers hypothesized that, similar to tumors, atherosclerotic plaques might contain substantial clonal cell populations identifiable through somatic mutations. They aimed to characterize the mutational landscape of plaques to explore the extent of these clonal populations and gain new insights into the pathology of atherosclerosis.

Methodology

The study performed deep whole-exome sequencing (WES) on DNA from 67 samples derived from the carotid plaques of 13 patients undergoing carotid endarterectomy. For comparison, they analyzed 28 samples from non-atherosclerotic arteries (5 ascending thoracic aortas and 23 internal thoracic arteries) from 11 patients undergoing coronary artery bypass surgery. Matched DNA from blood leukocytes (buffy coat) for each patient served as a normal reference, allowing the team to distinguish plaque-confined somatic mutations from germline variants and circulating hematopoietic mutations. The high sequencing coverage (average 700x) enabled the detection of mutations with variant allele frequencies (VAFs) as low as 1%. The VAF represents the fraction of DNA reads carrying the mutation, and for diploid cells, the clonal cell frequency is estimated as twice the VAF.

Key Findings: Somatic Mutations and Local Clonal Expansion

The study's primary finding was the striking difference between diseased and healthy arteries. Somatic mutations were identified in 12 out of the 13 carotid plaques investigated. In contrast, no mutations meeting the detection threshold were found in any of the 11 non-atherosclerotic artery samples.

The mutational burden in the plaques was significant, with an average of 37.8 somatic mutations per plaque (ranging from 0 to 125). These mutations led to the formation of clonal cell populations of considerable size, with clonal cell frequencies ranging from 1% to as high as 30.6% (median: 5.4%). This indicates that in some plaque samples, nearly one-third of the cells shared a common mutated ancestor. The findings were validated using droplet digital PCR (ddPCR) on a subset of mutations, which confirmed the VAFs obtained from WES.

By segmenting individual plaques and sequencing them separately, the researchers demonstrated that these mutated clones were not small, isolated pockets but could span considerable physical distances. In several cases, a single mutation was detected across multiple segments of the same plaque, indicating a physical clonal extent of at least 4 to 16 millimeters.

Mapping Mutations Within the Plaque Architecture

In a detailed analysis of four plaques with well-preserved morphology, the study provided insights into the spatial distribution of these clones. They observed that the medial layer of the artery, which lies beneath the plaque, had markedly fewer mutations compared to the overlying intimal plaque tissue. For instance, in one patient, a mutation in the RBPJ gene was found in the media, but the overlying plaque layers contained a much higher density and diversity of mutations.

Crucially, some clones appeared to span both the media and the intima. A notable example was a clone with a mutation in the OPN4 gene, which was present in 5% of cells in a medial sample but expanded to constitute 31% of cells in an adjacent intimal sample. This pattern is consistent with the known behavior of SMCs migrating from the media into the intima and proliferating to contribute to plaque growth. The data suggest that while the disease process is concentrated in the intima, it may be seeded by cells originating from the media.

The study also found that the sum of clonal cell frequencies in some samples exceeded 100%, implying that some cells must carry more than one mutation and that multiple distinct clones coexist within the same plaque region. This finding argues against a purely monoclonal origin for plaques and instead supports a model of "polyclonality," where multiple clones of significant size contribute to the plaque's cellular mass.

Mutated Genes Are Not Randomly Distributed

The researchers investigated whether the identified mutations were merely random "passengers" or potential "drivers" conferring a selective advantage. While no single gene was mutated across multiple patients (no "hotspots"), the analysis revealed a non-random pattern.

A gene ontology analysis of the 334 mutated genes showed a significant enrichment for genes associated with the contractile apparatus, desmosomes (cell adhesion structures), and the mitotic spindle pole. By cross-referencing these genes with single-cell RNA sequencing datasets from human plaques, the team found that the mutated genes related to the contractile apparatus were most highly expressed in SMCs and modulated "fibromyocyte" cell populations. This suggests that mutations in these genes could disrupt normal SMC function, potentially promoting the pathological proliferation and phenotypic switching that drives atherosclerosis.

Contribution of Circulating CHIP Clones

In a separate analysis, the study investigated the contribution of circulating clones from the blood. They screened for CHIP-related mutations and found that 6 of the 13 plaque donors (46%) were CHIP carriers. The VAFs of these mutations in the blood corresponded to clonal cell frequencies ranging from 2.6% to 34%.

Significantly, the same CHIP mutations found in the blood were also detected in the matched plaque samples. This provides direct evidence that circulating hematopoietic cells carrying CHIP mutations infiltrate the plaque tissue and can constitute a substantial fraction of the plaque's cellular population. For example, in one patient, a CHIP mutation in the NOTCH2 gene was present in 21.6% of blood cells and contributed to 13.4%–18.4% of the cells across multiple plaque samples. Unlike the plaque-confined mutations enriched in SMC-related genes, the CHIP-mutated genes were primarily expressed in macrophage populations within the plaque.

Implications and Future Directions

This research establishes that atherosclerotic plaques are a landscape of coexisting, large, mutated cell clones derived from both local vascular cells and infiltrating hematopoietic cells. While the data do not support a strict monoclonal origin for the entire plaque, they reveal that clonal expansion is a fundamental process in its development.

The authors propose that somatic mutations can now serve as invaluable, naturally occurring genetic "tags" to trace cell lineages and study cellular dynamics in human atherosclerosis with unprecedented precision. This overcomes the limitations of previous methods, such as X-chromosome inactivation studies. Future studies combining single-cell sequencing with mutation detection could definitively identify the cell types carrying specific mutations and map their clonal evolution.

The findings also raise a critical question: are these mutations drivers of the disease or merely passengers? The non-random distribution of mutations in functionally relevant pathways suggests they may play a causal role by promoting cell proliferation and dysfunction. If confirmed, this could open up entirely new therapeutic avenues for atherosclerosis, potentially targeting the specific pathways affected by these somatic mutations.

In conclusion, this landmark study fundamentally advances our understanding of the cellular basis of atherosclerosis. It demonstrates that the disease is not just a process of lipid accumulation and inflammation but also one of somatic evolution, akin to a benign tumor, where mutated cell populations expand to shape the pathological landscape of the artery wall.

Research cited

#plaque#chip#atherosclerosis#carotid#cardiovasculardisease#cardiovascular#stemcells#genetics
← newer: CNN: large study finds marijuana use doubles the risk of dyiolder: Frustration that EPA is cancelling PFAS drinking-water limit →